Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade
Executive Summary
Following an exchange decision that Samsung BioLogics should remain listed, the company has vowed to improve management transparency by beefing up internal controls and supervision over accounting. The decision is set to ease worries over the possible negative impact of an accounting probe on contract development and manufacturing orders, although the company still faces a court battle with financial authorities over its accounting standards.
You may also be interested in...
Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
Samsung BioLogics Faces Penalties As Authorities Conclude 'Intentional' Accounting Violation
Things have turned for the worse for Samsung BioLogics after a second review by financial authorities in South Korea over its accounting related to corporate control over Samsung Bioepis, resulting in fines, a recommendation for dismissal of its CEO, and a suspension in trading in its stock. The company is poised to face tough times ahead, although it reiterates it hasn’t violated any accounting rules and has vowed again to seek legal steps.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.